Stem Cell Therapy for Sepsis and Septic Shock

Sepsis and septic shock are medical emergencies with no drug that directly fixes the underlying immune dysregulation, which has made researchers look at mesenchymal stem cells (MSCs) as a possible add-on therapy. This article covers what MSCs are thought to do in sepsis, what human and animal studies actually show so far, and why — despite a genuinely encouraging safety record and an intriguing mortality signal — this remains an experimental, trial-only approach with no FDA-approved stem cell product for sepsis.

Overview

Sepsis occurs when the body's response to an infection spirals out of control and starts damaging its own tissues and organs; septic shock is the most severe form, marked by dangerously low blood pressure and organ failure. Standard treatment — antibiotics, IV fluids, vasopressors, and organ support in the ICU — saves many lives but does nothing to directly correct the runaway inflammation and immune exhaustion that drive the worst outcomes. That gap is why cell-based immunomodulation has drawn serious research interest.

How It's Thought to Work

MSCs are being studied in sepsis for their immune-regulating rather than tissue-replacing properties. In laboratory and animal models, they appear to calm the "cytokine storm" by shifting the balance between pro- and anti-inflammatory signals, help immune cells clear bacteria more effectively, support the repair of damaged blood vessel linings, and reduce the vascular leakage that drives organ failure in shock. This mechanism is well-documented in preclinical work but is harder to prove definitively in critically ill humans, whose immune states vary enormously from patient to patient.

What the Evidence Shows

The foundation for human testing came from a 2016 systematic review and meta-analysis in eLife, which pooled 18 animal studies (980 animals) and found MSC treatment cut mortality substantially in preclinical sepsis models (odds ratio 0.27), a consistent effect across doses, cell sources, and timing. The authors were candid that no animal study used proper blinding or randomization and that publication bias likely inflated the true effect — but the consistency was strong enough to justify moving into people.

That first human test, the CISS Phase I trial published in the American Journal of Respiratory and Critical Care Medicine (2018), gave nine septic shock patients a single IV infusion of bone-marrow-derived MSCs at escalating doses up to 3 million cells/kg. The genuinely good news: no serious infusion-related adverse events occurred, comparable to 21 observational control patients. This was a safety trial only, not designed to prove the therapy works — but it cleared the path for larger studies.

A 2025 pooled meta-analysis in Discover Medicine combined 11 clinical trials (360 sepsis/septic shock patients, 191 treated with MSCs vs. 169 controls). Mortality trended lower with MSC therapy (odds ratio 0.54) — a promising signal — though it landed right at the edge of statistical significance (p=0.05) and didn't cross the line for the pooled group as a whole. Notably, patients who received three or more infusions had significantly better survival (odds ratio 0.3, p=0.03), while single-dose patients saw no benefit — suggesting dosing frequency may matter a great deal. Safety again held up: no significant increase in adverse events, and treated patients had shorter ICU and hospital stays.

Larger, controlled follow-up work is now underway, including a Phase II randomized trial (UC-CISS) at the University of British Columbia testing umbilical-cord-derived MSCs. Sepsis research has a difficult history — several previously "promising" drugs (such as activated protein C) looked good in early trials and failed or were withdrawn once tested in larger populations — so this encouraging early signal needs to be read with that history in mind, not as proof the therapy works.

Who Might Be a Candidate

Right now, MSC therapy for sepsis exists only inside formal research protocols, not as an available treatment:

• Patients with sepsis-induced organ dysfunction or septic shock who are candidates for enrollment in an active, IRB-approved clinical trial
• Individuals whose ICU team is evaluating investigational adjunct therapies alongside standard sepsis care
• Anyone researching options should check ClinicalTrials.gov for currently recruiting trials rather than seeking treatment outside a registered study

Anyone offered MSC "sepsis treatment" outside a registered, IRB-approved trial should treat that as unproven and potentially unsafe in critically ill patients — this is not an approved or commercially available option.

Bottom Line

MSC therapy for sepsis has cleared an important early bar: it appears safe in the human trials done so far, and pooled data hint at a real mortality benefit — especially with repeated dosing — that's genuinely worth following. But no phase III trial has confirmed it works, no MSC product is FDA-approved for sepsis or septic shock, and the field's history of early promise not surviving larger trials means this remains investigational. Anyone interested should look at enrolling in an active, registered clinical trial rather than seeking it as a treatment today.